Download PDF
Horm Metab Res 2006; 38(9): 592-597
DOI: 10.1055/s-2006-951307
Original Clinical

© Georg Thieme Verlag KG Stuttgart · New York

Insertion/Deletion Polymorphism on ACE Gene is Associated with Endothelial Dysfunction in Young Patients with Hypertension

A. Penesova 1 , E. Cizmarova 2 , R. Kvetnansky 1 , J. Koska 1 , B. Sedlakova 3 , O. Krizanova 3
  • 1Institute of Experimental Endocrinology Slovak Academy of Sciences, Bratislava, Slovakia
  • 2Cardiology Clinic, Karlova Ves, Bratislava, Slovakia
  • 3Institute of Molecular Physiology and Genetics Slovak Academy of Sciences, Bratislava, Slovakia
Further Information

Publication History

Received 31 January 2006

Accepted after revision 29 May 2006

Publication Date:
18 September 2006 (online)

Also available at
    Permissions and Reprints

Abstract

Endothelial dysfunction, insulin resistance (IR) and genetic predispositions are important risk factors of hypertension. Aim of our study was to test the hypothesis, whether insertion/deletion (I/D) polymorphism on the angiotensin converting enzyme (ACE) gene and M235T polymorphism on angiotesinogen gene (AGT) correlates with parameters of insulin sensitivity and plasminogen activator inhibitor (PAI-1) levels in newly diagnosed hypertensive patients as compared with normotensive controls. Blood pressure (BP), fasting plasma glucose, insulin, epinephrine, norepinephrine and PAI-1 concentrations were determined in 30 male patients with hypertension grade 1 (HT) and in 31 matched healthy subjects (NT). Insulin resistance was estimated using IR HOMA formula. Patients with HT had increased levels of PAI-1, norepinephrine, fasting plasma insulin levels, IR HOMA (p<0.001) compared to controls. Subjects (HT and NT) with DD and ID genotype had a significantly higher systolic BP (p<0.05) and PAI-1 compared to those with II genotype. Homozygous subjects 235T had a higher systolic BP and higher levels of epinephrine and norepinephrine than heterozygous or homozygous M235 (p<0.05). In conclusion, no association was found between M235T polymorphism and insulin resistance or PAI-1 levels, but results indicate relationship between I/D polymorphism of the ACE gene and plasma PAI-1 levels in the early stage of hypertension.

Key words

Blood pressure - insertion/deletion (I/D) polymorphism - angiotensin converting enzyme (ACE) - hypertension - PAI-1

References

  • 1 Jeunemaitre X, Soubrier F, Kotelevtsev YV, Lifton RP, Williams CS, Charru A, Hunt SC, Hopkins PN, Williams RR, Lalouel JM. et al . Molecular basis of human hypertension: role of angiotensinogen.  Cell. 1992;  71 169-180
    CrossrefPubMedGoogle Scholar
  • 2 Horan MJ, Lenfant C. Epidemiology of blood pressure and predictors of hypertension.  Hypertension. 1990;  15 ((2 Suppl)) I20-I24
    PubMedGoogle Scholar
  • 3 Perry IJ, Whincup PH, Shaper AG. Environmental factors in the development of essential hypertension.  Br Med Bull. 1994;  50 246-259
    PubMedGoogle Scholar
  • 4 Schjoedt KJ, Jacobsen P, Rossing K, Boomsma F, Parving HH. Dual blockade of the renin- angiotensin-aldosterone system in diabetic nephropathy: the role of aldosterone.  Horm Metab Res. 2005;  37 ((Suppl 1)) 4-8
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Walker WG, Whelton PK, Saito H, Russell RP, Hermann J. Relation between blood pressure and renin, renin substrate, angiotensin II, aldosterone and urinary sodium and potassium in 574 ambulatory subjects.  Hypertension. 1979;  1 287-291
    PubMedGoogle Scholar
  • 6 Krizanova O, Obdrzalkova D, Polakova H, Jelok I, Hudecova S. Molecular variants of the renin-angiotensin system components in the Slovak population.  Physiol Res. 1997;  46 357-361
    PubMedGoogle Scholar
  • 7 Rotimi C, Morrison L, Cooper R, Oyejide C, Effiong E, Ladipo M. Angiotensinogen gene in human hypertension: lack of an association of the 235 T allele among African Americans.  Hypertension. 1994;  24 591-594
    PubMedGoogle Scholar
  • 8 Sethi AA, Nordestgaard BG, Tybjaerg-Hansen A. Angiotensinogen gene polymorphism, plasma angiotensinogen, and risk of hypertension and ischemic heart disease: a meta-analysis.  Arterioscler Thromb Vasc Biol. 2003;  23 1269-1275
    PubMedGoogle Scholar
  • 9 Ueda S, Elliott HL, Morton JJ, Connel JMC. Enhanced pressor response to angiotensin I in normotensive men with the ACE deletion allele.  Hypertension. 1995;  25 1266-1269
    PubMedGoogle Scholar
  • 10 Soubrier F, Wei L, Hubert C, Clauser E, Alhens-Gelas F, Corvol P. Molecular biology of the angiotensin I converting enzyme. II. Structure-function. Gene polymorphism and clinical implications.  J Hypertens. 1993;  11 599-604
    PubMedGoogle Scholar
  • 11 Mendonca I, Freitas IA, Sousa CA, Gomes S, Faria P, Drumond A, Silva G, Araujo JJ, Freitas S, Ornelas I, Andrade G, Coelho AP, Silva PM, Cardoso A, Brehm AA, dos Reis RP. Polymorphism of the ACE gene is associated with extent and severity of coronary disease.  Rev Port Cardiol. 2004;  23 1605-1611
    PubMedGoogle Scholar
  • 12 Takahashi K, Nakamura H, Kubota I, Takahashi N, Tomoike H. Association of ACE gene polymorphisms with coronary artery disease in a northern area of Japan.  Jpn Heart J. 1995;  36 557-564
    PubMedGoogle Scholar
  • 13 Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, Arveiler D, Luc G, Bard JM, Bara L, Ricard S. et al . Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction.  Nature. 1992;  359 641-644
    CrossrefPubMedGoogle Scholar
  • 14 Evans AE, Poirier O, Kee F Lecerf L, McCrum E, Falconer T, Crane J, O'Rourke DF, Cambien F. Polymorphism of the angiotensin-converting enzyme gene in subjects who die from coronary heart disease.  Q J Med. 1994;  87 211-214
    PubMedGoogle Scholar
  • 15 Makris TK, Tsoukala C, Krespi P, Hatzizacharias A, Gialeraki A, Papargyriou J, Votteas V, Mandalaki T. Haemostasis balance disorders in patients with essential hypertension.  Thromb Res. 1997;  88 99-107
    CrossrefPubMedGoogle Scholar
  • 16 Junker R, Heinrich J, Schulte H, Erren M, Assmann G. Hemostasis in normotensive and hypertensive men: results of the PROCAM study. The prospective cardiovascular Munster study.  J Hypertens. 1998;  16 917-923
    PubMedGoogle Scholar
  • 17 Oliver JJ, Webb DJ, Newby DE. Stimulated tissue plasminogen activator release as a marker of endothelial function in humans.  Arterioscler Thromb Vasc Biol. 2005;  25 2470-2479
    CrossrefPubMedGoogle Scholar
  • 18 Ridker PM, Gaboury CL, Conlin PR, Seely EW, Williams GH, Vaughan DE. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function.  Circulation. 1993;  87 1969-1973
    PubMedGoogle Scholar
  • 19 Feener EP, Northrup JM, Aiello LP, King GL. Angiotensin II induces plasminogen activator inhibitor-1 and -2 expressions in vascular endothelial and smooth muscle cells.  J Clin Invest. 1995;  95 1353-1362
    CrossrefPubMedGoogle Scholar
  • 20 Makris TK, Stavroulakis GA, Dafni UG, Gialeraki AE, Krespi PG, Hatzizacharias AN, Tsoukala CG, Vythoulkas JS, Kyriakidis MK. ACE/DD genotype is associated with hemostasis balance disturbances reflecting hypercoagulability and endothelial dysfunction in patients with untreated hypertension.  Am Heart J. 2000;  140 760-765
    CrossrefPubMedGoogle Scholar
  • 21 Pankow JS, Arnett DK, Borecki IB, Hunt SC, Eckfeldt JH, Folsom AR, Djousse L. Lack of association between the angiotensin-converting enzyme insertion/deletion polymorphism and plasminogen activator inhibitor-1 antigen levels in the National Heart, Lung, and Blood Institute Family Heart Study.  Blood Coagul Fibrinolysis. 2000;  11 551-558
    CrossrefPubMedGoogle Scholar
  • 22 Jeng JR, Harn HJ, Yueh KC, Jeng CY, Shieh SM. Plasminogen activator inhibitor-1 and angiotensin I converting enzyme gene polymorphism in patients with hypertension.  Am J Hypertens. 1998;  11 235-239
    CrossrefPubMedGoogle Scholar
  • 23 Panahloo A, Andres C, Mohamed-Ali V, Gould MM, Talmud P, Humphries SE, Yudkin JS. The insertion allele of the ACE gene I/D polymorphism. A candidate gene for insulin resistance?.  Circulation. 1995;  92 3390-3393
    PubMedGoogle Scholar
  • 24 Perticone F, Ceravolo R, Iacopino S, Cloro C, Ventura G, Maio R, Gulletta E, Perrotti N, Mattioli PL. Relationship between angiotensin-converting enzyme gene polymorphism and insulin resistance in never-treated hypertensive patients.  J Clin Endocrinol Metab. 2001;  86 172-178
    CrossrefPubMedGoogle Scholar
  • 25 Ceravolo R, Maio R, Cuda G, Scozzafava A, Sciacqua A, Vatrano M, Bellieni G, D'Angelo G, Schipani FA, Sesti G, Perticone F. Relation of fasting insulin related to insertion/deletion polymorphism of angiotensin-converting enzyme-gene and cardiac mass in never-treated patients with systemic hypertension.  Am J Cardiol. 2003;  92 1234-1237
    CrossrefPubMedGoogle Scholar
  • 26 Mondry A, Loh M, Liu P, Zhu AL, Nagel M. Polymorphisms of the insertion/deletion ACE and M235T AGT genes and hypertension: surprising new findings and meta-analysis of data.  BMC Nephrol. 2005;  6 1
    CrossrefPubMedGoogle Scholar
  • 27 Sheu WH, Lee WJ, Jeng CY, Young MS, Ding YA, Chen YT. Angiotensinogen gene polymorphism is associated with insulin resistance in nondiabetic men with or without coronary heart disease.  Am Heart J. 1998;  136 125-131
    CrossrefPubMedGoogle Scholar
  • 28 ESH/ECS 2003 - European Society of Hypetension . European Society of Cardiology guidelines for the management of arterial hypertension.  J Hypertens. 2003;  21 1011-1053
    CrossrefPubMedGoogle Scholar
  • 29 Friedewald WT, Levy RI, Fredrickson DS. Estimation of concentration of low- density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.  Clin Chem. 1972;  18 499-502
    CrossrefPubMedGoogle Scholar
  • 30 Peuler JD, Johnson GA. Simultaneous single isotope radioenzymatic assay of plasma noepinephrin, epinephrine and dopamine.  Life Sci. 1977;  21 625-636
    CrossrefPubMedGoogle Scholar
  • 31 Matthews Dr, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.  Diabetologia. 1985;  28 412-419
    Google Scholar
  • 32 Russ AP, Maerz W, Ruzicka V, Stein U, Gross W. Rapid detection of the hypertension-associated Met235 → Thr allele of the human angiotensinogen gene.  Hum Mol Genet. 1993;  2 609-610
    PubMedGoogle Scholar
  • 33 Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I converting enzyme gene accounting for half the variance of serum enzyme levels.  J Clin Invest. 1992;  86 1343-1346
    PubMedGoogle Scholar
  • 34 Jamerson KA, Julius S, Gudbrandsson T, Andrersson O, Brant DO. Reflex sympathetic activation induces acute insulin resistance in the human forearm.  Hypertension. 1993;  21 618-623
    PubMedGoogle Scholar
  • 35 Julius S, Jamerson K. Sympathetics, insulin resistance and coronary risk in hypertension: the ‘chicken-and-egg’ question.  J Hypertens. 1994;  12 495-502
    PubMedGoogle Scholar
  • 36 Celentano A, Mancini FP, Crivaro M, Palmieri V, de Stefano V, Ferrere LA, Di Minno G, de Simone G. Influence of cardiovascular risk factors on relation between angiotensin converting enzyme-gene polymorphism and blood pressure in arterial hypertension.  J Hypertens. 1998;  16 985-991
    CrossrefPubMedGoogle Scholar
  • 37 Martin LJ, Woo JG, Daniels SR, Goodman E, Dolan LM. The Relationships of Adiponectin with Insulin and Lipids Are Strengthened with Increasing Adiposity.  J Clin Endocrinol Metab. 2005;  90 4255-4259
    CrossrefPubMedGoogle Scholar
  • 38 Janan-Delene B, Chagnaud C, Raccah D, Alessi MC, Juhan-Vague I, Vague P. Visceral fat as a main determinant of plasminogen activator inhibitor-1 in women.  Int J Obes. 1998;  22 312-317
    CrossrefPubMedGoogle Scholar
  • 39 Ferrannini E, Buzzigoli G, Bonadonna R, Ciociaro D, Oleggini M, Graziadei L, Pedrinelli R, Brandi L, Bevilacqua S. Insulin resistance in essential hypertension.  N Engl J Med. 1987;  317 350-357
    CrossrefPubMedGoogle Scholar
  • 40 Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities. The role of insulin resistance and the sympathoadrenal system.  N Engl J Med. 1996;  334 374-381
    CrossrefPubMedGoogle Scholar
  • 41 Laakso M, Edelman SV, Brechtel G, Baron AD. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese men.  J Clin Invest. 1990;  85 1844-1852
    CrossrefPubMedGoogle Scholar
  • 42 Freedman BI, Rich SS, Sale MM, Heiss G, Djousse L, Pankow JS, Province MA, Rao DC, Lewis CE, Chen YD, Beck SR. HyperGEN Investigators. Genome-wide scans for heritability of fasting serum insulin and glucose concentrations in hypertensive families.  Diabetologia. 2005;  48 661-668
    CrossrefPubMedGoogle Scholar
  • 43 Vitale C, Mercuro G, Castiglioni C, Cornoldi A, Tulli A, Fini M, Volterrani M, Rosano GM. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome.  Cardiovasc Diabetol. 2005;  4 6
    CrossrefPubMedGoogle Scholar
  • 44 Arcaro G, Cretti A, Balzano S, Lechi A, Muggeo M, Bonora E, Bonadonna RC. Insulin causes endothelial dysfunction in humans: sites and mechanisms.  Circulation. 2002;  105 576-582
    CrossrefPubMedGoogle Scholar
  • 45 Reaven GM. Compensatory hyperinsulinemia and the development of an atherogenic lipoprotein profile: the price paid to maintain glucose homeostasis in insulin-resistant individuals.  Endocrinol Metab Clin North Am. 2005;  34 49-62
    CrossrefPubMedGoogle Scholar

Correspondence

Adela PenesovaM.D. 

Institute of Experimental Endocrinology·Slovak Academy of Sciences

Vlarska 3·833 06 Bratislava·Slovakia

Phone: +421/2/54 77 49 42

Fax: +421/2/54 77 42 47

Email: Adela.Penesova@savba.sk

      >